These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778 [TBL] [Abstract][Full Text] [Related]
5. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing. Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426 [TBL] [Abstract][Full Text] [Related]
6. A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report. Cui J; Chen X; Zhai Q; Chen N; Li X; Zhang Y; Wang H; Bian X; Gao N; Chen D; Chen Z; Zhang S; Chen Y Diagn Pathol; 2023 Feb; 18(1):19. PubMed ID: 36765365 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464 [TBL] [Abstract][Full Text] [Related]
8. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D. Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study. Yu S; Sun Z; Zong L; Yan J; Yu M; Chen J; Lu Z J Gynecol Oncol; 2022 May; 33(3):e38. PubMed ID: 35320887 [TBL] [Abstract][Full Text] [Related]
11. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063 [TBL] [Abstract][Full Text] [Related]
12. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis. Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130 [TBL] [Abstract][Full Text] [Related]
13. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Church DN; Briggs SE; Palles C; Domingo E; Kearsey SJ; Grimes JM; Gorman M; Martin L; Howarth KM; Hodgson SV; ; Kaur K; Taylor J; Tomlinson IP Hum Mol Genet; 2013 Jul; 22(14):2820-8. PubMed ID: 23528559 [TBL] [Abstract][Full Text] [Related]
14. A Multiplex SNaPshot Assay is a Rapid and Cost-Effective Method for Detecting POLE Exonuclease Domain Mutations in Endometrial Carcinoma. Devereaux KA; Steiner DF; Ho C; Gomez AJ; Gilks B; Longacre TA; Zehnder JL; Howitt BE; Suarez CJ Int J Gynecol Pathol; 2022 Nov; 41(6):541-551. PubMed ID: 34907997 [TBL] [Abstract][Full Text] [Related]
15. Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours. Andrianova MA; Chetan GK; Sibin MK; Mckee T; Merkler D; Narasinga RK; Ribaux P; Blouin JL; Makrythanasis P; Seplyarskiy VB; Antonarakis SE; Nikolaev SI J Pathol; 2017 Nov; 243(3):331-341. PubMed ID: 28805995 [TBL] [Abstract][Full Text] [Related]
16. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients. Wu Q; Zhang N; Xie X BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827 [TBL] [Abstract][Full Text] [Related]
17. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441 [TBL] [Abstract][Full Text] [Related]
18. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas. Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215 [TBL] [Abstract][Full Text] [Related]
19. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability. Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608 [TBL] [Abstract][Full Text] [Related]
20. POLE exonuclease domain mutations in endometrial carcinoma: a case report. Pasciuto MP; Felicioni L; Zampacorta C; Ferro B; Di Marino P; Primavera FC; Lucidi A; Rossetti R; Barbareschi M; Marchetti A; Buttitta F; D'Angelo E Pathologica; 2023 May; 1(1):181-185. PubMed ID: 37216304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]